First Time Loading...

JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200

Watchlist Manager
JiangSu WuZhong Pharmaceutical Development Co Ltd Logo
JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200
Watchlist
Price: 10.59 CNY 0.19% Market Closed
Updated: May 15, 2024
Section:
 

Relative Value

The Relative Value of one JiangSu WuZhong Pharmaceutical Development Co Ltd stock under the Base Case scenario is 6.96 CNY. Compared to the current market price of 10.59 CNY, JiangSu WuZhong Pharmaceutical Development Co Ltd is Overvalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
6.96 CNY
Overvaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.5
P/S
P/S
Price to Sales
3.5
vs History
6
vs Industry
35
Median 3Y
2.8
Median 5Y
2.7
Industry
2.5
Forward
3.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-75.7
Median 5Y
-64.3
Industry
23.4
Forward
2 074
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
3
Median 3Y
-79.7
Median 5Y
-21.7
Industry
17.9
More Details
340.8
P/FCFE
P/FCFE
Price to FCFE
340.8
vs History
7
vs Industry
2
Median 3Y
29.6
Median 5Y
22.8
Industry
24.1
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
3
vs Industry
19
Median 3Y
2.9
Median 5Y
2.6
Industry
2.1
More Details
3.5
EV/S
EV/S
Enterprise Value to Sales
3.5
vs History
6
vs Industry
35
Median 3Y
2.9
Median 5Y
2.7
Industry
2.6
Forward
3.4
More Details
13.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
13.2
vs History
3
vs Industry
16
Median 3Y
10.1
Median 5Y
9.6
Industry
5.2
More Details
272.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
272.3
vs History
12
vs Industry
1
Median 3Y
-13.7
Median 5Y
-13.3
Industry
13.9
Forward
85.9
More Details
272.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
272.3
vs History
12
vs Industry
1
Median 3Y
-13.7
Median 5Y
-13.3
Industry
17.5
Forward
91.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
3
Median 3Y
-80.2
Median 5Y
-23.9
Industry
16.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
1
Median 3Y
-40.9
Median 5Y
-28.5
Industry
18.1
More Details
3.1
EV/IC
EV/IC
Enterprise Value to IC
3.1
vs History
3
vs Industry
27
Median 3Y
2.4
Median 5Y
2.2
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
JiangSu WuZhong Pharmaceutical Development Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200
7.5B CNY 3.5 -405.1 272.3 272.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
726.1B USD 20.2 118.3 57.9 65.9
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK 16.6 45.4 33.9 37.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
364.3B USD 4.3 9.5 11.7 15.2
US
Merck & Co Inc
NYSE:MRK
325.9B USD 5.3 141.3 35.2 57.5
UK
AstraZeneca PLC
LSE:AZN
189.8B GBP 5 37.7 175 279.1
CH
Novartis AG
SIX:NOVN
183.4B CHF 3.4 11.5 8.8 12.8
CH
Roche Holding AG
SIX:ROG
179.1B CHF 3 15.6 8.9 10.5
US
Pfizer Inc
NYSE:PFE
160.2B USD 2.9 -518.6 12.8 20.4
P/E Multiple
Earnings Growth
CN
JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200
Average P/E: 54.2
Negative Multiple: -405.1 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
118.3
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.4
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.5
-20%
US
Merck & Co Inc
NYSE:MRK
141.3
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.7
168%
CH
Novartis AG
SIX:NOVN
11.5
15%
CH
Roche Holding AG
SIX:ROG
15.6
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -518.6
680%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.